免费获得国外相关药品，最快 1 个工作日回馈药物信息
Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam (VERIDAT)
The semiconductor (cadmium-zinc-telluride, CZT) cameras significantly increase detection sensitivity in Single Photon Emission Computer Tomoscintigraphy (SPECT)(1) . The clinical routine applications of these cameras are today mainly limited to myocardial tomoscintigraphy with CZT dedicated cameras. Several studies whose one was done in Hospital of Nancy, made it possible to demonstrate a good diagnosis agreement between conventional cameras and semiconductor cameras in this indication, with better image quality obtained with semiconductor cameras (2). Today, so-called "wide field" semiconductor cameras are available in the clinic and allow for any type of SPECT examination. A comparative study between conventional and semiconductor cameras has been conducted for bone scintigraphy, and shows diagnostic superiority with this new type of camera (3).
In addition, the new VERITON-CT ™ (Spectrum Dynamics Medical) camera has 12 mobile CZT-based detectors positioned around the patient allowing tomographic acquisitions and focusing the acquisition on the organ studied. This camera has a sensitivity of detection higher than that of conventional cameras and thus reduces the activity injected into the patient and / or the recording time.
To date, no study has compared the two types of cameras in nuclear neurology and in particular, for the SPECT DaTSCAN ™ imaging of the pre-synaptic dopaminergic pathway.
DaTSCAN ™ exam is used in clinical routine:
- for the diagnosis of Parkinson's disease or related diseases when in doubt with an essential tremor (4) or
- if suspicion of Lewy body disease, if in doubt with Alzheimer's disease (5). If the interpretation of DaTSCAN ™ exam is first visual, the quantification may increase accuracy diagnosis (6). Also, the database creation specific to each type of camera is recommended(7).
The purpose of this study is to compare the diagnostically relevant informations and the quantitative analysis provided by the DaTSCAN™ SPECT, recorded on the conventional camera and recorded on the semiconductor camera VERITON-CT™
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Parkinson Disease | Procedure: DaTSCAN SPECT/CT in VERITON-CT camera | Not Applicable |
The clinical study is monocentric, interventional, non randomized, with minimal risk and constraints.
All patients going to the nuclear medicine department for a DaTSCAN exam will be able to participate in this study if they understood study informations given by the physician and if they signed the inform consent.
In first, patients will have a DaTSCAN™ SPECT on a conventional camera and after, they will have DaTSCAN™ SPECT on VERITON-CT™ camera with two records: one in focus striatum mode and the second in focus brain mode.
The attenuation correction will be made with the computer tomography (CT) recorded at the same time as the SPECT (SPECT/CT)
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 96 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Diagnostic |
| Official Title: | Comparative Study of DaTSCAN ™ Cerebral SPECT Recorded by Conventional Anger Cameras and Semiconductor Camera (VERITON-CT ™) |
| Actual Study Start Date : | September 5, 2019 |
| Actual Primary Completion Date : | September 3, 2020 |
| Actual Study Completion Date : | September 3, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: all included patients will have the same procedure
After the conventional DaTSCAN SPECT/CT exam in conventional camera, all patients included will have two recordings of DaTSCAN SPECT/CT in semiconductor CZT (cadmium zinc telluride) camera; one focused on the striatum and the other focused on the total brain
|
Procedure: DaTSCAN SPECT/CT in VERITON-CT camera
the intervention is based on two recordings in camera VERITON-CT ; the first, in focus striatum mode and the second in brain focus mode
|
- Degree of concordance (Kappa) of the exams results of different records [ Time Frame: 16 months ]comparison between the exam results (positive diagnosis of Parkinson disease or Lewy bodies dementia versus differential diagnosis) in conventional camera and the one obtained with the VERITON-CT in striatum focus mode
- Degree of concordance (Kappa) of the exams results of different recordings [ Time Frame: 16 months ]comparison between the exam results (positive diagnosis of Parkinson disease or Lewy bodies dementia versus differential diagnosis) in conventional camera and the one obtained with the VERITON-CT in brain focus mode
- Degree of concordance (Kappa) of the exams results of different recordings [ Time Frame: 16 months ]comparison between the exam results (positive diagnosis of Parkinson disease versus differential diagnosis) in conventional camera and the one obtained with the VERITON-CT in striatum focus mode
- Degree of concordance (Kappa) of the exams results of different recordings [ Time Frame: 16 months after the first enrollment ]comparison between the exam results (positive diagnosis of Lewy bodies dementia versus differential diagnosis) in conventional camera and the one obtained with the VERITON-CT in striatum focus mode
- ratios of uptake obtained with conventional camera and on the striatum focus record with VERITON-CT [ Time Frame: immediately after SPECT-CT exam ]the uptake ratios are:caudate nuclei/occipital cortex, putamen/occipital cortex, to the right and caudate nuclei/medium cingulate cortex, putamen/medium cingulate cortex to left, obtained with conventional camera and on the striatum focus record with VERITON-CT camera
- quality scores of images from conventional camera and from VERITON (striatum) [ Time Frame: immediately after SPECT-CT exam ]0= very bad quality and impossible to do a diagnosis, 1=bad quality and difficult diagnosis, 2= medium quality, 3 = good quality and 4= excellent quality
- recording activity in striatal area for the images from conventional camera and from VERITON (striatum) [ Time Frame: immediately after SPECT-CT exams ]recorded activities will be reported by injected MBq for the images obtained with the conventional camera and with VERITON striatum focus record
- score of diagnosis agreement for the images interpretation by 3 physicians [ Time Frame: 18 months ]The agreement will be between conventional record and striatum focus record with VERITON camera
- uptake ratios on the conventional record and on the focus brain record with VERITON [ Time Frame: after each SPECT/CT exams ]the uptake ratios are:caudate nuclei/occipital cortex, putamen/occipital cortex, to the right and caudate nuclei/medium cingulate cortex, putamen/medium cingulate cortex to left, obtained with conventional camera and on the brain focus record with VERITON-CT camera
- quality scores of images from conventional camera and from VERITON (brain) [ Time Frame: immediately after SPECT-CT exams ]0= very bad quality and impossible to do a diagnosis, 1=bad quality and difficult diagnosis, 2= medium quality, 3 = good quality and 4= excellent quality
- recording activity in striatal area for the images from conventional camera and from VERITON (brain) [ Time Frame: 18 months ]recorded activities will be reported by injected MegaBecquerel (MBq) for the images obtained with the conventional camera and with VERITON brain focus record
- diagnosis agreement for the interpretation by 3 physicians between conventional and VERITON (brain) [ Time Frame: 18 months ]The agreement will be between conventional record and brain focus record with VERITON camera
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- all patients over 18 years sent to Datscan SPECT/CT
- patients understanding and having signed the informed consent form.
- without contraindication to have the scintigraphy
- patient subject to a medical benefits scheme
Exclusion Criteria:
- known allergy to the one of the components of Datscan
- pregnant, parturient or breastfeeding woman
- major person under legal protection (any form of public guardianship)
- major person unable to express consent
- person deprived of liberty due to judicial or administrative decision.
| France | |
| CHRU of Nancy | |
| Vandoeuvre les Nancy cedex, France, 54511 | |
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Submitted Date ICMJE | June 6, 2019 | ||||
| First Posted Date ICMJE | June 10, 2019 | ||||
| Last Update Posted Date | January 27, 2021 | ||||
| Actual Study Start Date ICMJE | September 5, 2019 | ||||
| Actual Primary Completion Date | September 3, 2020 (Final data collection date for primary outcome measure) | ||||
| Current Primary Outcome Measures ICMJE |
Degree of concordance (Kappa) of the exams results of different records [ Time Frame: 16 months ] comparison between the exam results (positive diagnosis of Parkinson disease or Lewy bodies dementia versus differential diagnosis) in conventional camera and the one obtained with the VERITON-CT in striatum focus mode
|
||||
| Original Primary Outcome Measures ICMJE |
Degree of concordance (Kappa) of the exams results of different records [ Time Frame: 5 minutes/ patient ] comparison between the exam results (positive diagnosis of Parkinson disease or Lewy bodies dementia versus differential diagnosis) in conventional camera and the one obtained with the VERITON-CT in striatum focus mode
|
||||
| Change History | |||||
| Current Secondary Outcome Measures ICMJE |
Degree of concordance (Kappa) of the exams results of different recordings [ Time Frame: 16 months ] comparison between the exam results (positive diagnosis of Parkinson disease or Lewy bodies dementia versus differential diagnosis) in conventional camera and the one obtained with the VERITON-CT in brain focus mode
|
||||
| Original Secondary Outcome Measures ICMJE |
Degree of concordance (Kappa) of the exams results of different records [ Time Frame: 5 minutes/patient ] comparison between the exam results (positive diagnosis of Parkinson disease or Lewy bodies dementia versus differential diagnosis) in conventional camera and the one obtained with the VERITON-CT in brain focus mode
|
||||
| Current Other Pre-specified Outcome Measures |
|
||||
| Original Other Pre-specified Outcome Measures |
|
||||
| Descriptive Information | |||||
| Brief Title ICMJE | Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam | ||||
| Official Title ICMJE | Comparative Study of DaTSCAN ™ Cerebral SPECT Recorded by Conventional Anger Cameras and Semiconductor Camera (VERITON-CT ™) | ||||
| Brief Summary |
The semiconductor (cadmium-zinc-telluride, CZT) cameras significantly increase detection sensitivity in Single Photon Emission Computer Tomoscintigraphy (SPECT)(1) . The clinical routine applications of these cameras are today mainly limited to myocardial tomoscintigraphy with CZT dedicated cameras. Several studies whose one was done in Hospital of Nancy, made it possible to demonstrate a good diagnosis agreement between conventional cameras and semiconductor cameras in this indication, with better image quality obtained with semiconductor cameras (2). Today, so-called "wide field" semiconductor cameras are available in the clinic and allow for any type of SPECT examination. A comparative study between conventional and semiconductor cameras has been conducted for bone scintigraphy, and shows diagnostic superiority with this new type of camera (3). In addition, the new VERITON-CT ™ (Spectrum Dynamics Medical) camera has 12 mobile CZT-based detectors positioned around the patient allowing tomographic acquisitions and focusing the acquisition on the organ studied. This camera has a sensitivity of detection higher than that of conventional cameras and thus reduces the activity injected into the patient and / or the recording time. To date, no study has compared the two types of cameras in nuclear neurology and in particular, for the SPECT DaTSCAN ™ imaging of the pre-synaptic dopaminergic pathway. DaTSCAN ™ exam is used in clinical routine:
The purpose of this study is to compare the diagnostically relevant informations and the quantitative analysis provided by the DaTSCAN™ SPECT, recorded on the conventional camera and recorded on the semiconductor camera VERITON-CT™ |
||||
| Detailed Description |
The clinical study is monocentric, interventional, non randomized, with minimal risk and constraints. All patients going to the nuclear medicine department for a DaTSCAN exam will be able to participate in this study if they understood study informations given by the physician and if they signed the inform consent. In first, patients will have a DaTSCAN™ SPECT on a conventional camera and after, they will have DaTSCAN™ SPECT on VERITON-CT™ camera with two records: one in focus striatum mode and the second in focus brain mode. The attenuation correction will be made with the computer tomography (CT) recorded at the same time as the SPECT (SPECT/CT) |
||||
| Study Type ICMJE | Interventional | ||||
| Study Phase ICMJE | Not Applicable | ||||
| Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Diagnostic |
||||
| Condition ICMJE | Parkinson Disease | ||||
| Intervention ICMJE | Procedure: DaTSCAN SPECT/CT in VERITON-CT camera
the intervention is based on two recordings in camera VERITON-CT ; the first, in focus striatum mode and the second in brain focus mode
|
||||
| Study Arms ICMJE | Experimental: all included patients will have the same procedure
After the conventional DaTSCAN SPECT/CT exam in conventional camera, all patients included will have two recordings of DaTSCAN SPECT/CT in semiconductor CZT (cadmium zinc telluride) camera; one focused on the striatum and the other focused on the total brain
Intervention: Procedure: DaTSCAN SPECT/CT in VERITON-CT camera
|
||||
| Publications * | Not Provided | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status ICMJE | Completed | ||||
| Actual Enrollment ICMJE |
96 | ||||
| Original Estimated Enrollment ICMJE | Same as current | ||||
| Actual Study Completion Date ICMJE | September 3, 2020 | ||||
| Actual Primary Completion Date | September 3, 2020 (Final data collection date for primary outcome measure) | ||||
| Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
||||
| Sex/Gender ICMJE |
|
||||
| Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||
| Accepts Healthy Volunteers ICMJE | No | ||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
| Listed Location Countries ICMJE | France | ||||
| Removed Location Countries | |||||
| Administrative Information | |||||
| NCT Number ICMJE | NCT03980418 | ||||
| Other Study ID Numbers ICMJE | PSS2019/VERIDAT-VERGER-VS | ||||
| Has Data Monitoring Committee | Yes | ||||
| U.S. FDA-regulated Product |
|
||||
| IPD Sharing Statement ICMJE | Not Provided | ||||
| Responsible Party | Central Hospital, Nancy, France | ||||
| Study Sponsor ICMJE | Central Hospital, Nancy, France | ||||
| Collaborators ICMJE | Not Provided | ||||
| Investigators ICMJE | Not Provided | ||||
| PRS Account | Central Hospital, Nancy, France | ||||
| Verification Date | September 2020 | ||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||
